July 2, 2026 11:44 am
Genomics
Genomic Testing Cooperative Highlights Expanded Role of Comprehensive CSF-Based Molecular Profiling Following NCCN Guideline Update for Inoperable High-Grade Gliomas and Glioblastomas
GTC highlights Liquid Trace® CSF testing as NCCN updates support CSF-based molecular profiling for inoperable gliomas and glioblastomas.
June 30, 2026 6:00 am
Publications
Liquid biopsy profiling in CTCL: a pilot feasibility study
A pilot feasibility study published in Blood Neoplasia demonstrates the potential of comprehensive cfDNA + cfRNA liquid biopsy for molecular profiling in cutaneous T-cell lymphoma (CTCL). Using GTC’s high-depth NGS platform,
June 17, 2026 11:43 am
Press Releases
Genomic Testing Cooperative to Exhibit and Present Research at 2026 ASCO Annual Meeting
GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
May 27, 2026 1:02 pm
Press Releases
GTC and Dr. Maher Albitar Featured in Houston Business Journal
Genomic Testing Cooperative and its founder and CEO, Dr. Maher Albitar, were recently featured in the Houston Business Journal in a “Face to Face” profile highlighting
May 18, 2026 11:38 am
Publications
ASCO 2026 Abstracts
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile. Presenter: Adam Albitar, MD
April 27, 2026 12:27 pm
Press Releases
GTC opens Houston laboratory, expanding national precision oncology network
New central U.S. location strengthens testing capacity and turnaround times while positioning GTC within the Texas Medical Center ecosystem HOUSTON — March 12, 2026 — Genomic
March 12, 2026 4:00 am
January 7, 2026 11:32 am
January 7, 2026 11:27 am
January 7, 2026 11:25 am